Drugmakers Prod European Stocks To Post-Easter Rally
at Investor's Business Daily - 41 mins ago
European exchanges were high scorers on the world map Tuesday, as investors returned with vigor from the four-day holiday. Germany's Frankfurt Exchange led the pack, with the DAX index vaulting 2% higher. In Italy, Milano's FTSE MIB punched up 1.5%....
A Doozy of a Pharma Rumor
Brian Orelli, The Motley Fool - Motley Fool - 47 mins ago
The latest health care acquisition rumor is a doozy. According to multiple news outlets, Pfizer was in talks with AstraZeneca to acquire the company for over $100 billion, although the companies apparently broke off talks. Interestingly, this...
Most active New York Stock Exchange-traded stocks
AP - 1 hr 14 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - 1 hr 14 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Billionaire Ken Fisher's Top Stock Picks
Nicole Seghetti, The Motley Fool - Motley Fool - Tue Apr 22, 3:08PM CDT
Money managers must disclose their stock holdings every quarter, giving investors like you and me a peek into their portfolios. Based on his firm's first-quarter 13F SEC filing, here are multibillion-dollar fund manager Ken Fisher's top three stock...
This is the 1 Thing AstraZeneca Should Do to Improve Shareholder Value
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 1:05PM CDT
It's only Tuesday and this has already been an exciting week in the health-care sector. I'm speaking of the news this weekend that pharma giant Pfizer reportedly considered making a $101 billion bid for U.K.-based rival AstraZeneca , a 27%...
Midday Glance: Pharmaceuticals companies
AP - Tue Apr 22, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Active Equities under the Scanner -- Research on JPMorgan Chase, Pfizer, General Motors, and Nokia
PR Newswire - Tue Apr 22, 12:13PM CDT
The trading session on Monday, April 21, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,449.25, up 0.25% and the NASDAQ Composite closed at 4,121.55, up 0.64%. The S&P 500 finished the session 0.38% higher at 1,871.89. The gains were broad based as eight out of ten sectors finished on a higher note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include JPMorgan Chase & Co. (NYSE: JPM), Pfizer Inc. (NYSE: PFE), General Motors Co. (NYSE: GM) and Nokia OYJ (NYSE: NOK). Free technical research on JPM, PFE, GM and NOK can be downloaded upon signing up at:
3 Health Care Stocks Moving The Sector Upward
at The Street - Tue Apr 22, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Novartis reshapes business with GSK, Lilly deals
By JOHN HEILPRIN - AP - Tue Apr 22, 11:02AM CDT
GENEVA (AP) — Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co. that heralds more restructuring in the fast-changing industry.
Pharma deals give stocks a lift
By The Associated Press - AP - Tue Apr 22, 10:55AM CDT
LONDON (AP) — A flurry of deals in the pharmaceutical sector helped to shore up global stock markets on Tuesday.
Novartis Reshapes Portfolio via GSK, Eli Lilly Deals
at The Street - Tue Apr 22, 10:40AM CDT
The Swiss company announces four multibillion-dollar transactions including the $16 billion purchase of GlaxoSmithKline's oncology business.
Today's Health-Care Stocks to Watch: Allergan, Inc., AstraZeneca, Pfizer, and Valeant Pharmaceutical
George Budwell, The Motley Fool - Motley Fool - Tue Apr 22, 9:34AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Allergan , AstraZeneca plc , Pfizer , and Valeant Pharmaceuticals . Valeant makes a play for Allergan Allergan shares are up double digits this...
Stock Market News for April 22, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 9:06AM CDT
Benchmarks ended in the green zone yesterday as investors were encouraged by better-than-expected corporate earnings results
Global Human Reproductive ((Infertility: Drugs and Procedures & Contraceptives: Drugs and Devices) Technologies Market 2013-2019
M2 - Tue Apr 22, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcxdpd/human) has announced the addition of the "Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Human reproductive technologies include procedures and therapies for conceiving or controlling pregnancy by means of artificial and/or semi artificial medical solutions. Reproductive technologies are used to treat infertility problems in males as well as in females. Since the last decade, a remarkable prevalence of infertility has been observed worldwide and its morbidity rate is rapidly growing. Changes in lifestyle such as delay in bearing the first child, use of contraceptive pills, increased alcohol consumption and smoking are some of the factors leading to increase in the infertility rate globally, due to which the human reproductive technologies market is experiencing rise in demand. Human reproductive technologies are mainly categorized on the basis of infertility treatments and contraceptive technologies. The infertility drugs market is analyzed based on the big seven brands (by sales) such as, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn. Viagra, Gonal-f and AndroGel are the major drugs in their respective drug classes, which are preferred majorly for treating different causes of infertility. Further, the human reproductive technologies market is analyzed by various infertility treatment procedures which is led by the intrauterine insemination (IUI) procedure owing to low procedural cost and less complexity in performing the procedure. Contraceptive technologies market is segmented into contraceptive drugs such as oral contraceptive pills, contraceptive injectables and topical contraceptives; and devices such as male and female contraceptive devices. Within the contraceptives market, the market share of male contraceptives was the largest due to factors such as ease of use, lack of side effects and higher availability. The market will be driven by factors such as increase in conception rate, rising prevalence of unwanted pregnancies and sexually transmitted diseases (STDs). The global human reproductive technologies market is highly fragmented in nature with many companies currently competing in the market. Well established market players such as Merck & Co., Inc., Ferring International Center S.A., Pfizer, Inc. Merck Serono and Bayer AG dominate this market with their proprietary products and predatory growth strategies. Patent repositories of the established market players are restraining the entry and growth of new players entering the market. The global human reproductive technologies market is categorized into the following segments: Infertility Drugs - Gonal-f (recombinant follitropin alfa) - Follistim AQ (follitropin beta) - AndroGel (testosterone) - Testim (testosterone) - Viagra (sildenafil citrate) - Cialis (tadalafil) - Levitra/Staxyn (vardenafil) Infertility Procedures - In Vitro Fertilization (IVF) - Intracytoplasmic Sperm Injection (ICSI) - Zygote Intrafallopian Transfer (ZIFT) - Gamete Intrafallopian Transfer (GIFT) - Intrauterine Insemination (IUI) Contraceptive Technologies - Drugs - - Oral Contraceptive Pills - - Contraceptive Injectables - - Topical Contraceptives - Devices - - Male Contraceptive Devices (Male Condoms) - - Female Contraceptive Devices Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Human Reproduction Technologies Market, by Infertility Treatment - Global Human Reproductive Technologies Market, by Contraceptive Technologies - Global Human Reproductive Technologies Market Revenue, by Geography - Recommendations - Company Profiles - Abbott Laboratories, Inc. - Actavis, Inc. - Bayer AG - Church & Dwight, Co. Inc. - Cook Medical, Inc. - Ferring International Center S.A. - Johnson & Johnson - Merck & Co., Inc. - Merck Serono - Pfizer, Inc. - Reckitt Benckiser Group plc - Teva Pharmaceutical Industries Ltd. - Warner Chilcott plc For more information visit http://www.researchandmarkets.com/research/bcxdpd/human
Valeant, Ackman make $45.6B Allergan bid
AP - Tue Apr 22, 7:45AM CDT
NEW YORK (AP) — Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.
Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Business Wire - Tue Apr 22, 7:01AM CDT
Pfizer Inc. (NYSE
European Stocks Rise, Led by Pharma Sector News
at The Street - Tue Apr 22, 5:17AM CDT
The main European markets open in a buoyant mood after the Easter break.
Global Brain Tumor Therapeutics Pipeline Review 2014 - Analysis of 9 Companies & 19 Drug Profiles
M2 - Tue Apr 22, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9tl8j/brain_tumor) has announced the addition of the "Brain Tumor - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Tumor and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Brain Tumor - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Tumor and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Brain Tumor pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Pfizer Inc. - Bayer AG - Hutchison MediPharma Limited - Advantagene, Inc. - Oncovir, Inc. - DEKK-TEC, Inc. - CalAsia Pharmaceuticals, Inc. - Tolero Pharmaceuticals, Inc. - Dong-A Socio Holdings Co Ltd Drug Profiles - Antibody to Inhibit PGRN for Brain Tumor - Bay-846 - Bi-specific Antibody For Brain Tumor Therapy - Bispecific T-Cell Engager - CIGB-128 - DA-3607 - DC/AAT DC/AAT-Flu DC/KLH - Dendritic Cell Vaccine - GliAtak - HMPL-813 - HOOI - Neural Stem Cells - PF-06463922 - Poly-ICLC - Small Molecule To Inhibit Hsp90 Alpha and TRAP1 For Brain Cancer - TP-0903 - VAL-083 - VO-101 - diaziquone For more information visit http://www.researchandmarkets.com/research/s9...rain_tumor